NY-ESO-1 immunotherapy for multiple myeloma

References

• Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101–1107
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan K R, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma.[see comment][erratum appears in N Engl J Med 2004;350:2628]. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality. Bone Marrow Transplant 2005; 35: 215–224
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 wihtout thalidomide: comparison with total therapy 1: role of intensified induction and post-transplant consolidation therapies. Blood 2006; 107: 2633–2638
   PubMed Web of Science ®Google Scholar
• Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoetic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole D H, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Morris C, Desikan R, Martin S R, Munshi N, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574–2579
   PubMed Web of Science ®Google Scholar
• Mohty M, Boiron J M, Damaj G, Michallet A S, Bay J O, Faucher C, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77–84
   PubMed Web of Science ®Google Scholar
• Lokhorst H M, Schattenberg A, Cornelissen J J, van Oers M H, Fibbe W, Russell I, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031–3037
   PubMed Web of Science ®Google Scholar
• Davis I D, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4( + ) and CD8( + ) T cell responses in humans. Proc Natl Acad Sci (USA) 2004; 101: 10697–10702
   PubMed Web of Science ®Google Scholar
• Jager E. Vaccine strategies against NY-ESO-1 in cancer patients. Cancer Imm 2005; 5: 12
   Google Scholar
• Davis I D, Schnurr M, Hopkins W, Miloradovic L, Old L J, et al. NY-ESO-1 protein-based cancer vaccines: the Melbourne experience. Cancer Imm 2005; 5: 13
   Google Scholar
• Dudley M E, Wunderlich J R, Yang J C, Sherry R M, Topalian S L, Restifo N P, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–2357
   PubMed Web of Science ®Google Scholar
• Ratta M, Curti A, Fogli M, Pantucci M, Viscomi G, Tazzari P, et al. Efficient presentation of tumor idiotype to autologous T cells by CD83( + ) dendritic cells derived from highly purified circulating CD14( + ) monocytes in multiple myeloma patients. Exp Hematol 2000; 28: 931–940
   PubMed Web of Science ®Google Scholar
• Yi Q, Desikan K R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002; 117: 297–305
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke C D, Kobrin C B, Benko F A, Sternas L A, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–1177
   PubMed Web of Science ®Google Scholar
• Neelapu S S, Baskar S, Kwak L W. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. J Cancer Res Clin Oncol 2001; 127(2)R14–R19
   PubMed Web of Science ®Google Scholar
• Timmerman J M, Czerwinski D K, Davis T A, Hsu F J, Benike C, Hao Z M, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526
   PubMed Web of Science ®Google Scholar
• Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004; 18: 139–145
   PubMed Web of Science ®Google Scholar
• Stevenson F K, Ottensmeier C H, Johnson P, Zhu D, Buchan S L, McCann K J, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci (USA) 2004; 101(Suppl 2)14646–14652
   PubMed Web of Science ®Google Scholar
• Sahota S S, Townsend M, Stevenson F K. Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. Meth Mol Med 2005; 113: 105–119
   PubMedGoogle Scholar
• Timmerman J M, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000; 164: 4797–4803
   PubMed Web of Science ®Google Scholar
• Liso A, Stockerl-Goldstein K E, Auffermann-Gretzinger S, Benike C J, Reichardt V, van Beckhoven A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 621–627
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 2003; 88: 1139–1149
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Okada C Y, Liso A, Benike C J, Stockerl-Goldstein K E, Engleman E G, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood 1999; 93: 2411–2419
   PubMed Web of Science ®Google Scholar
• Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996; 26: 2671–2679
   PubMed Web of Science ®Google Scholar
• Treon S P, Maimonis P, Bua D, Young G, Raje N, Mollick J, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96: 3147–3153
   PubMed Web of Science ®Google Scholar
• Neelapu S S, Munshi N C, Jagannath S, Watson T M, Pennington R, Reynolds C, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005; 36: 315–323
   PubMed Web of Science ®Google Scholar
• Bendandi M, Rodriguez-Cavillo M, Inoges S, de Cerio A, Perez-Simon J, Rodriguez-Cabellero A. Combined vaccination with idiotype-pulsed dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006; 47: 29–37
   PubMed Web of Science ®Google Scholar
• Szmania S, Cottler-Fox M, Rosen N, Viswamitra S, Moreno A, Pomtree M, et al. A novel strategy for combining immunotherapy with high dose chemotherapy and auto-transplantation in high risk multiple myeloma. Blood 2004; 104: 798a, Abstract # 2920
   Web of Science ®Google Scholar
• Borello I, Biedrzycki B, Sheets N, Racke F, Huff C A, Loper K, et al. Autologous tumor combined with a GM-CSF-secreting cell line vaccine following autologous stem cell transplant (ASCT) in multiple myeloma. Proc Am Soc Clin Ocol 2003; 22: 167
   Google Scholar
• Raje N, Hideshima T, Davies F E, Chauhan D, Treon S P, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004; 125: 343–352
   PubMed Web of Science ®Google Scholar
• Hao S, Chan T, Xiang J. Genetically engineered myeloma cell vaccine. Meth Mol Med 2005; 113: 235–244
   PubMedGoogle Scholar
• Xia D, Chan T, Xiang J. Dendritic cell/myeloma hybrid vaccine. Meth Mol Med 2005; 113: 225–233
   PubMedGoogle Scholar
• Treon S P, Shima Y, Grossbard M L, Preffer F I, Belch A R, Pilarski L M, et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 2000; 11: 107–111
   PubMed Web of Science ®Google Scholar
• Goto T, Kennel S J, Abe M, Takishita M, Kosaka M, Solomon A, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84: 1922–1930
   Google Scholar
• Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Comm 1999; 258: 583–591
   PubMed Web of Science ®Google Scholar
• Lim S H, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001; 97: 1508–1510
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Robinson W R, Lim S H. Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen. Eur J Haematol 2004; 73: 280–284
   PubMed Web of Science ®Google Scholar
• Maecker B, Sherr D H, Vonderheide R H, von Bergwelt-Baildon M S, Hirano N, Anderson K S, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003; 102: 3287–3294
   PubMed Web of Science ®Google Scholar
• Wu K J, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220–224
   PubMed Web of Science ®Google Scholar
• Qian J, Wang S, Yang J, Xie J, Lin P, Freeman M E, 3, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 2005; 11: 8808–8815
   PubMed Web of Science ®Google Scholar
• Brugger W, Buhring H J, Grunebach F, Vogel W, Kaul S, Muller R, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 1999; 17: 1535–1544
   PubMed Web of Science ®Google Scholar
• Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, et al. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem 2004; 52: 549–554
   PubMed Web of Science ®Google Scholar
• Dadabayev A R, Wang Z, Zhang Y, Zhang J, Robinson W R, Lim S H. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics. Am J Hematol 2005; 80: 6–11
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001; 61: 6846–6850
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Xue Y, Bumm K, Hahn A B, Lim S H. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunol 2001; 31: 2277–2283
   PubMed Web of Science ®Google Scholar
• Rew S B, Peggs K, Sanjuan I, Pizzey A R, Koishihara Y, Kawai S, et al. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res 2005; 11: 3377–3384
   PubMed Web of Science ®Google Scholar
• Maecker B, von Bergwelt-Baildon M S, Anderson K S, Vonderheide R H, Anderson K C, Nadler L M, et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol 2005; 141: 558–562
   PubMed Web of Science ®Google Scholar
• Gribben J G, Ryan D P, Boyajian R, Urban R G, Hedley M L, Beach K, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005; 11: 4430–4436
   PubMed Web of Science ®Google Scholar
• Reddish M, MacLean G D, Koganty R R, Kan-Mitchell J, Jones V, Mitchell M S, et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998; 76: 817–823
   PubMed Web of Science ®Google Scholar
• Jungbluth A A, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005; 106: 167–174
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Osman K, Teruya-Feldstein J, Filippa D, Hedvat C V, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Imm 2003; 3: 9
   PubMedGoogle Scholar
• Taylor B, Reiman T, Pittman J, Keats J, de Bruin D, Mant M, et al. SSX cancer testis antigens are expressed in most multiple myeloma patients. J Immunother 2005; 28: 564–575
   PubMed Web of Science ®Google Scholar
• Szmania S, Bennett G, Batchu R, Rosen N, Gupta S, Xie J, et al. Dendritic cells pulsed with NY-ESO-1 and MAGE-3 peptides stimulate myeloma specific cytotoxic T lymphocytes. Blood 2002; 100: 399a
   Web of Science ®Google Scholar
• Chen Y T, Scanlan M J, Sahin U, Tureci O, Gure A O, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci (USA) 1997; 94: 1914–1918
   PubMed Web of Science ®Google Scholar
• Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998; 76: 903–908
   PubMed Web of Science ®Google Scholar
• Alpen B, Gure A O, Scanlan M J, Old L J, Chen Y T. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene 2002; 297: 141–149
   PubMed Web of Science ®Google Scholar
• Scanlan M J, Simpson A J, Old L J. The cancer/testis genes: review, standardization, and commentary. Cancer Imm 2004; 4: 1
   PubMedGoogle Scholar
• Chen Y T, Boyer A D, Viars C S, Tsang S, Old L J, Arden K C. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogen Cell Gen 1997; 79: 237–240
   PubMedGoogle Scholar
• Zendman A J, Ruiter D J, van Muijen G N. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003; 194: 272–288
   PubMed Web of Science ®Google Scholar
• Jungbluth A A, Chen Y T, Stockert E, Busam K J, Kolb D, Iversen K, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92: 856–860
   PubMed Web of Science ®Google Scholar
• Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199–2204
   PubMed Web of Science ®Google Scholar
• Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Imm 2003; 3: 10
   PubMedGoogle Scholar
• Fujita S, Wada H, Jungbluth A A, Sato S, Nakata T, Noguchi Y, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10: 6551–6558
   PubMed Web of Science ®Google Scholar
• Sarcevic B, Spagnoli G C, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, et al. Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 2003; 64: 443–449
   PubMed Web of Science ®Google Scholar
• Kienstra M A, Neel H B, Strome S E, Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003; 25: 457–463
   PubMed Web of Science ®Google Scholar
• Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006; 118: 123–128
   Google Scholar
• Odunsi K, Jungbluth A A, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63: 6076–6083
   PubMed Web of Science ®Google Scholar
• Maio M, Coral S, Sigalotti L, Elisei R, Romei C, Rossi G, et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 2003; 88: 748–754
   PubMed Web of Science ®Google Scholar
• Schultz-Thater E, Noppen C, Gudat F, Durmuller U, Zajac P, Kocher T, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 2000; 83: 204–208
   PubMed Web of Science ®Google Scholar
• Sharma P, Gnjatic S, Jungbluth A A, Williamson B, Herr H, Stockert E, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003; 3: 19
   PubMedGoogle Scholar
• Wang Y, Wu X J, Zhao A L, Yuan Y H, Chen Y T, Jungbluth A A, et al. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun 2004; 4: 11
   PubMedGoogle Scholar
• Mischo A, Kubuschok B, Ertan K, Preuss K D, Romeike B, Regitz E, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006; 118: 696–703
   PubMed Web of Science ®Google Scholar
• Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 2001; 61: 4671–4674
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania S M, Zhan F, Gupta S K, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105: 3939–3944
   PubMed Web of Science ®Google Scholar
• van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156–1164
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol 2003; 120: 3–9
   PubMed Web of Science ®Google Scholar
• de Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002; 21: 6848–6857
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757
   PubMed Web of Science ®Google Scholar
• Hong J A, Kang Y, Abdullaev Z, Flanagan P T, Pack S D, Fischette M R, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65: 7763–7774
   PubMed Web of Science ®Google Scholar
• De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 7327–7335
   PubMed Web of Science ®Google Scholar
• Tarte K, de Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts [see comment]. Blood 2002; 100: 1113–1122
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Mellerin M P, Labarriere N, Jego G, Moreau-Aubry A, Harousseau J L, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000; 30: 803–809
   PubMed Web of Science ®Google Scholar
• Gure A O, Chua R, Williamson B, Gonen M, Ferrera C A, Gnjatic S, et al. Cancer-Testis genes are coordinately expressed and are markers of poor aoutcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055–8062
   PubMed Web of Science ®Google Scholar
• Harrison S J, Cook G. Immunotherapy in multiple myeloma – possibility or probability. Br J Haematol 2005; 130: 344–362
   PubMed Web of Science ®Google Scholar
• Jager E, Chen Y T, Drijfhout J W, Karbach J, Ringhoffer M, Jager D, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265–270
   PubMed Web of Science ®Google Scholar
• Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet M J, Champagne P, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8 + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000; 60: 4499–4506
   PubMed Web of Science ®Google Scholar
• Stockert E, Jager E, Chen Y T, Scanlan M J, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens [comment]. J Exp Med 1998; 187: 1349–1354
   PubMed Web of Science ®Google Scholar
• Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci (USA) 2000; 97: 4760–4765
   PubMed Web of Science ®Google Scholar
• Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, et al. Induction of primary NY-ESO-1 immunity: CD8 + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers. Proc Natl Acad Sci (USA) 2000; 97: 12198–12203
   PubMed Web of Science ®Google Scholar
• Zeng G, Wang X, Robbins P F, Rosenberg S A, Wang R F. CD4( + ) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci (USA) 2001; 98: 3964–3969
   PubMed Web of Science ®Google Scholar
• Khong H T, Rosenberg S A. Pre-existing immunity to tyrosinase-related protein (TRP)- 2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol 2002; 168: 951–956
   PubMed Web of Science ®Google Scholar
• Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande C, et al. Th1/Th2 CD4 + T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun 2004; 4: 12
   PubMedGoogle Scholar
• Huarte E, Karbach J, Gnjatic S, Bender A, Jager D, Arand M, et al. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4 + CD25- CD8- T cell clones. Cancer Immun 2004; 4: 15
   PubMedGoogle Scholar
• Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts B L, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci (USA) 2000; 97: 10917–10922
   PubMed Web of Science ®Google Scholar
• Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G, et al. CD8 + T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 2005; 106: 4217–4224
   PubMed Web of Science ®Google Scholar
• Hoeppner L H, Dubovsky J A, Dunphy E J, McNeel D G. Humoral immune responses to testits antigens in sera from patients with prostate cancer. Cancer Immun 2006; 6: 1–7
   PubMedGoogle Scholar
• Gnjatic S, Jager E, Chen W, Altorki N K, Matsuo M, Lee S Y, et al. CD8( + ) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci (USA) 2002; 99: 11813–11818
   PubMed Web of Science ®Google Scholar
• Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai T Y, et al. Immunodominant CD4 + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci (USA) 2004; 101: 9363–9368
   PubMed Web of Science ®Google Scholar
• Riker A I, Kammula U S, Panelli M C, Wang E, Ohnmacht G A, Steinberg S M, et al. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer 2000; 86: 818–826
   PubMed Web of Science ®Google Scholar
• Marincola F M, Jaffee E M, Hicklin D J, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181–273
   PubMedGoogle Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4( + ) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357–2368
   PubMed Web of Science ®Google Scholar
• Pardoll D M, Topalian S L. The role of CD4 + T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588–594
   PubMed Web of Science ®Google Scholar
• Toes R E, Ossendorp F, Offringa R, Melief C J. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753–756
   PubMed Web of Science ®Google Scholar
• Valmori D, Souleimanian N E, Hesdorffer C S, Ritter G, Old L J, Ayyoub M. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin Immunol 2005; 117: 24–30
   PubMed Web of Science ®Google Scholar
• Preuss K D, Regitz E, Neumann F, Pfreundschuh M. B-cell epitopes from the cancer testis antigen NY-ESO-1. Int J Cancer 2006; 118: 253
   PubMed Web of Science ®Google Scholar
• Zeng G, Aldridge M E, Wang Y, Pantuck A J, Wang A Y, Liu Y X, et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker [see comment]. Int J Cancer 2005; 114: 268–273
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich N P, Bachor O A, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213–219
   PubMed Web of Science ®Google Scholar
• Parker K C, Bednarek M A, Coligan J E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163–175
   PubMed Web of Science ®Google Scholar
• Dutoit V, Taub R N, Papadopoulos K P, Talbot S, Keohan M L, Brehm M, et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting [comment]. J Clin Invest 2002; 110: 1813–1822
   PubMed Web of Science ®Google Scholar
• Bownds S, Tong-On P, Rosenberg S A, Parkhurst M. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother 2001; 24: 1–9
   PubMed Web of Science ®Google Scholar
• Chen J L, Dunbar P R, Gileadi U, Jager E, Gnjatic S, Nagata Y, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165: 948–955
   PubMed Web of Science ®Google Scholar
• Le Gal F A, Ayyoub M, Dutoit V, Widmer V, Jager E, Cerottini J C, et al. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8 + T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother 2005; 28: 252–257
   PubMed Web of Science ®Google Scholar
• Khong H T, Yang J C, Topalian S L, Sherry R M, Mavroukakis S A, White D E, et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 2004; 27: 472–477
   PubMed Web of Science ®Google Scholar
• Khong H T, Wang Q J, Rosenberg S A. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004; 27: 184–190
   PubMed Web of Science ®Google Scholar
• Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang R F, et al. Generation of NY-ESO-1-specific CD4 + and CD8 + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002; 62: 3630–3635
   PubMed Web of Science ®Google Scholar
• Celis E. Getting peptide vaccines to work: just a matter of quality control? [see comment]. J Clin Invest 2002; 110: 1765–1768
   PubMed Web of Science ®Google Scholar
• Murphy R, Green S, Ritter G, Cohen L, Ryan D, Woods W, et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep Biochem Biotechnol 2005; 35: 119–134
   PubMed Web of Science ®Google Scholar
• Batchu R B, Moreno A M, Szmania S M, Bennett G, Spagnoli G C, Ponnazhagan S, et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res 2005; 65: 10041–10049
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Szmania S, Moreno A, Cottler-Fox M, Shaughnessy J, Barlogie B, et al. Vaccination with MAGE-3 protein can induce a potent immune response in a healthy donor which can be adoptively transferred via stem cell transplant to a multiple myeloma patient. Blood 2005; 106: 620a
   Web of Science ®Google Scholar
• Ennis F A, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999; 259: 256–261
   PubMed Web of Science ®Google Scholar
• Batchu R, Moreno A M, Szmania S, Gupta S K, Zhan F, Rosen N, et al. High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. Human Gene Ther 2003; 14: 1333–1345
   PubMed Web of Science ®Google Scholar
• Lopex L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol Immunother 2005; 26: 1–6
   Google Scholar
• Dhodapkar K M, Krasovsky J, Williamson B, Dhodapkar M V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells [comment]. J Exp Med 2002; 195: 125–133
   PubMed Web of Science ®Google Scholar
• Nagata Y SO, Matsuo M, Gnjatic S, Valmori D, Ritter G, Garrett W, et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. PNAS 2002; 99: 10629–10634
   PubMed Web of Science ®Google Scholar
• Cioca D P, Deak E, Cioca F, Paunescu V. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently corss-prime CD8 + T cells. J Immunother 2006; 29: 41–52
   PubMed Web of Science ®Google Scholar
• Chen W, Jackson H, Dimopoulos N, Tai T Y, Mifsud N A, Chen Q, et al. Systematic analysis of anti-NY-ESO-1 T cell responses reveals striking HLA-dependant immunodominance. J Immunother 2005; 28: 629
   Web of Science ®Google Scholar
• Smith C L, Mirza F, Pasquetto V, Tscharke D C, Palmowski M J, Dunbar P R, et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 2005; 175: 8431–8437
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Yang J C, Restifo N P. Cancer immunotherapy: moving beyond current vaccines [see comment]. Nature Med 2004; 10: 909–915
   PubMed Web of Science ®Google Scholar
• Dudley M E, Wunderlich J R, Robbins P F, Yang J C, Hwu P, Schwartzentruber D J, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–854
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350: 1461–1463
   PubMed Web of Science ®Google Scholar
• Coulie P G, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number. Curr Opin Immunol 2005; 17: 320–325
   PubMed Web of Science ®Google Scholar
• Xue S A, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005; 106: 3062–3067
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Z, Robbins P F, Khong H T, Rosenberg S A, Morgan R A. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174: 4415–4423
   PubMed Web of Science ®Google Scholar
• Brown R D, Pope B, Murray A, Esdale W, Sze D M, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992–2998
   PubMed Web of Science ®Google Scholar
• Letterio J J, Roberts A B. TGF-beta: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84: 244–250
   PubMedGoogle Scholar
• Powell D J, Jr, Parker L L, Rosenberg S A. Large-scale depletion of CD25 + regulatory T cells from patient leukapheresis samples. J Immunother 2005; 28: 403–411
   PubMed Web of Science ®Google Scholar
• Shi J, Szmania S, Rosen N, Moreno A, Walker R, Dupont B, et al. Killer immunoglobulin-like receptor ligand mismatched natural killer cell transfusions for multiple myeloma. Blood 2005; 106: 969a
   Web of Science ®Google Scholar
• Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8 + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470–476
   PubMed Web of Science ®Google Scholar
• Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo A M, Altomonte M, et al. Epigenetic immunomodulation of hematopoietic malignancies. Sem Oncol 2005; 32: 503–510
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, Jones P A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457–463
   PubMed Web of Science ®Google Scholar
• Weiser T S, Guo Z S, Ohnmacht G A, Parkhurst M L, Tong-On P, Marincola F M, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY- ESO-1. J Immunother 2001; 24: 151–161
   PubMed Web of Science ®Google Scholar
• Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201: 249–257
   PubMed Web of Science ®Google Scholar
• Tohnya T M, Figg W D. Immunomodulation of multiple myeloma. Cancer Biol Ther 2004; 3: 1060–1061
   PubMed Web of Science ®Google Scholar
• Davies F E, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [see comment]. Blood 2001; 98: 210–216
   PubMed Web of Science ®Google Scholar
• Szmania S, Yi Q, Cottler-Fox M, Rosen N, Freeman J, Kordsmeier B, et al. Clinical-grade myeloma ag pre-loaded DC vaccines retain potency after cryopreservation. Cytotherapy 2005; 7: 374–384
   PubMed Web of Science ®Google Scholar
• Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S, et al. Characterization of antigen-specific CD8 + T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun 2005; 5: 5
   PubMedGoogle Scholar
• Shackleton M, Davis I D, Hopkins W, Jackson H, Dimopoulos N, Tai T, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004; 4: 9
   PubMedGoogle Scholar
• Sharma P, Bajorin D F, Altorki N, Hiroyoshi N, Old L, Gnjatic S. Protein and DNA based vaccines with the NY-ESO-1 antigen in cancer patients. J Immunother 2005; 28: 659
   Web of Science ®Google Scholar
• Zarour H, Andrade P, Mandic M, Kudela P, Janjic B, Land S, et al. Randomized phaseI/II study of vaccination with CpG 7909, montanide ISA 720 and NY-ESO-1 peptides for patients with stage III/IV melanoma and NY-ESO-1 positive tumors: an interim analysis. J Immunother 2005; 28: 661
   Web of Science ®Google Scholar